Lili Mao

4.1k total citations
101 papers, 1.8k citations indexed

About

Lili Mao is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Lili Mao has authored 101 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 43 papers in Molecular Biology and 25 papers in Immunology. Recurrent topics in Lili Mao's work include Cutaneous Melanoma Detection and Management (45 papers), Melanoma and MAPK Pathways (35 papers) and CAR-T cell therapy research (34 papers). Lili Mao is often cited by papers focused on Cutaneous Melanoma Detection and Management (45 papers), Melanoma and MAPK Pathways (35 papers) and CAR-T cell therapy research (34 papers). Lili Mao collaborates with scholars based in China, Ethiopia and United States. Lili Mao's co-authors include Lu Si, Jun Guo, Chuanliang Cui, Xinan Sheng, Zhihong Chi, Bin Lian, Bixia Tang, Yan Kong, Siming Li and Xieqiao Yan and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Lili Mao

93 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lili Mao China 22 1.2k 859 458 197 172 101 1.8k
Christof Scheid Germany 28 648 0.6× 578 0.7× 472 1.0× 96 0.5× 54 0.3× 149 2.2k
Shiro Ohshima Japan 23 519 0.4× 809 0.9× 816 1.8× 94 0.5× 189 1.1× 77 2.3k
Elizabeth J. Davis United States 17 740 0.6× 403 0.5× 217 0.5× 324 1.6× 51 0.3× 64 1.5k
Kathrin Scheckenbach Germany 25 513 0.4× 464 0.5× 265 0.6× 143 0.7× 221 1.3× 64 1.4k
Kun Chen China 14 1.1k 0.9× 470 0.5× 718 1.6× 170 0.9× 121 0.7× 31 1.6k
Jan Eucker Germany 29 760 0.7× 1.0k 1.2× 122 0.3× 182 0.9× 284 1.7× 85 2.5k
Jun Saegusa Japan 25 266 0.2× 761 0.9× 640 1.4× 145 0.7× 207 1.2× 108 2.1k
Depei Wu China 28 958 0.8× 948 1.1× 671 1.5× 151 0.8× 226 1.3× 219 3.0k
Daniela Damiani Italy 31 1.1k 1.0× 843 1.0× 451 1.0× 202 1.0× 69 0.4× 134 3.0k
C. Darrell Jennings United States 20 299 0.3× 450 0.5× 602 1.3× 172 0.9× 98 0.6× 58 1.8k

Countries citing papers authored by Lili Mao

Since Specialization
Citations

This map shows the geographic impact of Lili Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lili Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lili Mao more than expected).

Fields of papers citing papers by Lili Mao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lili Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lili Mao. The network helps show where Lili Mao may publish in the future.

Co-authorship network of co-authors of Lili Mao

This figure shows the co-authorship network connecting the top 25 collaborators of Lili Mao. A scholar is included among the top collaborators of Lili Mao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lili Mao. Lili Mao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dai, Jie, Tianxiao Xu, Lifeng Li, et al.. (2025). Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis. Clinical and Translational Medicine. 15(1). e70169–e70169. 1 indexed citations
2.
Zhang, Jiaran, Lili Mao, Caili Li, et al.. (2025). Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma. Cancer Management and Research. Volume 17. 905–916. 1 indexed citations
3.
Day, Daphne, Vinod Ganju, Ki Y. Chung, et al.. (2025). First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors. British Journal of Cancer. 132(10). 905–912. 3 indexed citations
4.
Mao, Lili, Jie Dai, Xue Bai, et al.. (2024). Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study.. Journal of Clinical Oncology. 42(16_suppl). e21527–e21527. 1 indexed citations
5.
Dai, Jie, Fanshuang Zhang, Yanfeng Xi, et al.. (2024). Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications. Cancer Research Communications. 4(5). 1351–1362. 2 indexed citations
6.
Zheng, Jia, Sin Man Lam, Lili Mao, et al.. (2024). Cord blood ceramides facilitate early risk identification into childhood metabolic health. National Science Review. 11(10). nwae352–nwae352. 2 indexed citations
7.
Dai, Jie, Xiaoting Wei, Xue Bai, et al.. (2024). Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study. Dermatology Practical & Conceptual. 14(1). e2024026–e2024026. 1 indexed citations
8.
Mao, Lili, Jie Dai, Xue Bai, et al.. (2024). Neoadjuvant pembrolizumab and lenvatinib in resectable mucosal melanoma: NeoPlus study update.. Journal of Clinical Oncology. 42(16_suppl). 9580–9580. 2 indexed citations
9.
Lian, Bin, Yue Yang, Baomin Zheng, et al.. (2024). Efficacy and Safety of Postoperative Adjuvant Radiation Therapy in Resected Nasal Cavity and Paranasal Sinus Mucosal Melanoma: A Combined Analysis. International Journal of Radiation Oncology*Biology*Physics. 120(2). 528–536. 2 indexed citations
10.
Cui, Chuanliang, Xuan Wang, Bin Lian, et al.. (2022). OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study. Journal for ImmunoTherapy of Cancer. 10(4). e004307–e004307. 38 indexed citations
11.
Li, Siming, Xiaowen Wu, Xieqiao Yan, et al.. (2022). Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. Journal for ImmunoTherapy of Cancer. 10(2). e004036–e004036. 33 indexed citations
12.
Mao, Lili, Meiyu Fang, Xiaoting Wei, et al.. (2022). Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study. Clinical Cancer Research. 28(21). 4642–4648. 21 indexed citations
13.
Wang, Yang, Bin Lian, Lu Si, et al.. (2022). Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I–III. European Journal of Cancer. 175. 196–203. 3 indexed citations
14.
Yan, Xieqiao, Xinan Sheng, Zhihong Chi, et al.. (2021). Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. Journal of Clinical Oncology. 39(8). 881–889. 36 indexed citations
15.
Sheng, Xinan, Dengfeng Cao, Jianlin Yuan, et al.. (2018). Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. European Journal of Cancer. 100. 1–7. 37 indexed citations
16.
Bai, Xue, Yan Kong, Zhihong Chi, et al.. (2017). MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clinical Cancer Research. 23(20). 6120–6127. 72 indexed citations
17.
Peng, Lei, et al.. (2016). [Characteristics of sympathetic skin response in patients with multiple system atrophy].. PubMed. 96(33). 2620–2624. 3 indexed citations
18.
Dai, Jie, Yan Kong, Lu Si, et al.. (2013). Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib. Clinical Cancer Research. 19(24). 6935–6942. 38 indexed citations
19.
Lian, Bin, Lu Si, Chuanliang Cui, et al.. (2013). Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma. Clinical Cancer Research. 19(16). 4488–4498. 121 indexed citations
20.
Si, Lu, Yanyan Zhu, Xiaowei Xu, et al.. (2011). Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma. Clinical Cancer Research. 17(7). 1684–1691. 181 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christof Scheid Breakdown of academic impact, for papers by Shiro Ohshima Breakdown of academic impact, for papers by Elizabeth J. Davis Breakdown of academic impact, for papers by Kathrin Scheckenbach Breakdown of academic impact, for papers by Kun Chen Breakdown of academic impact, for papers by Jan Eucker Breakdown of academic impact, for papers by Jun Saegusa Breakdown of academic impact, for papers by Depei Wu Breakdown of academic impact, for papers by Daniela Damiani Breakdown of academic impact, for papers by C. Darrell Jennings
Rankless by CCL
2026